STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRAX
  4. [8-K] Praxis Precision Medicines, Inc. Reports Material Event

Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Praxis Precision Medicines reported positive early clinical results and a key regulatory milestone in severe childhood epilepsies. In the EMBRAVE Part A Phase 1/2 trial, elsunersen produced a 77% placebo-adjusted seizure reduction from baseline and 57% of pediatric SCN2A DEE patients experienced at least a 28-day seizure-free period. All nine patients, aged 2–12 years, continued into an open-label extension where efficacy was sustained for up to one year, and all elsunersen-treated patients showed functional improvements such as better sleep, motor function, muscle tone, attention or neuropsychomotor development. Elsunersen was well-tolerated with no drug-related serious adverse events, no discontinuations and no neuroinflammation signals at doses up to 8 mg, and most treatment-emergent adverse events were mild to moderate. Separately, the FDA accepted for priority review the company’s New Drug Application for relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, with a Prescription Drug User Fee Act target action date of September 27, 2026.

Positive

  • Elsunersen shows robust early efficacy and durability: EMBRAVE Part A reported a 77% placebo-adjusted seizure reduction and 57% of SCN2A DEE patients with at least a 28-day seizure-free period, with efficacy sustained in an open-label extension for up to one year.
  • Favorable safety and tolerability profile for elsunersen: No drug-related serious adverse events, no discontinuations, and no neuroinflammation signals were observed at doses up to 8 mg, with most treatment-emergent adverse events mild to moderate.
  • Regulatory acceleration for relutrigine: The FDA accepted relutrigine’s New Drug Application for SCN2A and SCN8A DEEs for priority review, setting a PDUFA target action date of September 27, 2026, which shortens the standard review timeline.

Negative

  • None.

Insights

Strong early efficacy for elsunersen and FDA priority review for relutrigine mark a materially positive update in rare pediatric epilepsies.

The EMBRAVE Part A trial shows elsunersen delivering a placebo-adjusted 77% seizure reduction in SCN2A DEE, with 57% of patients achieving at least 28 days seizure-free and functional gains across sleep and motor domains. Safety was favorable, with no drug-related serious adverse events and no neuroinflammation signals up to 8 mg.

Although the dataset is small at nine patients, efficacy persisting for up to one year in the open-label extension suggests durability within the observed period. The balance of seizure reduction, seizure-free intervals and multi-domain improvement is encouraging in a population with high unmet need, while mild-to-moderate treatment-emergent adverse events indicate a manageable profile in this early study.

Regulatory momentum is reinforced by FDA priority review of relutrigine’s NDA for SCN2A and SCN8A DEEs, with a PDUFA target action date of September 27, 2026. Priority review underscores FDA’s view that the application warrants expedited assessment, and subsequent disclosures around that decision point will be key to understanding potential commercial impact.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Placebo-adjusted seizure reduction 77% Elsunersen EMBRAVE Part A trial efficacy result (p=0.015, 95% CI 33–92)
Seizure-free patients 57% Patients with at least a 28-day seizure-free period on elsunersen
Patients enrolled 9 patients Randomized 3:1 to elsunersen or sham in EMBRAVE Part A
Treatment duration 24 weeks Dosing period before open-label extension in EMBRAVE Part A
Maximum elsunersen dose 8 mg No drug-related serious adverse events or neuroinflammation up to this dose
PDUFA target date September 27, 2026 FDA priority review action date for relutrigine NDA
Starting elsunersen dose 1 mg Initial dose with optional escalation based on seizure reduction and tolerability
Patient age range 2–12 years Pediatric SCN2A DEE population in EMBRAVE Part A
developmental and epileptic encephalopathy medical
"for the treatment of SCN2A and SCN8A DEEs"
A severe neurological condition that begins in infancy or early childhood, marked by frequent, hard-to-control seizures and slowing or loss of normal development such as movement, learning and communication. Think of it as a critical control system in a child’s brain that malfunctions and interferes with growth and daily function. For investors it signals a high unmet medical need, focused regulatory attention and the potential for significant commercial value — but also greater clinical and development risk for therapies.
open-label extension medical
"24 weeks, followed by an open-label extension"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.
treatment-emergent adverse events medical
"Most treatment-emergent adverse events (“TEAEs”) were mild to moderate"
Events or symptoms that either appear for the first time or get worse after a patient starts a treatment; think of new or intensified side effects that show up once medicine or a medical device is used. Investors watch these closely because they affect whether a therapy can gain regulatory approval, be prescribed widely, or face legal and commercial setbacks—similar to how early customer complaints can sink a new product’s prospects.
priority review regulatory
"the FDA has accepted for priority review the Company’s New Drug Application"
Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.
New Drug Application regulatory
"accepted for priority review the Company’s New Drug Application for relutrigine"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
Prescription Drug User Fee Act regulatory
"target action date under the Prescription Drug User Fee Act of September 27, 2026"
A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.
Understanding 8-K Material Events →
FALSE000168954800016895482026-04-062026-04-06

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 6, 2026
PRAXIS PRECISION MEDICINES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39620
47-5195942
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

Praxis Precision Medicines, Inc.
99 High Street, 30th Floor
Boston, Massachusetts 02110
(Address of principal executive offices, including zip code)
(617) 300-8460
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trade
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 


Item 8.01. Other Events.
Praxis Precision Medicines, Inc. (the “Company”) is providing the following business updates:
Elsunersen
The Company announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A development and epileptic encephalopathy (“DEE”). EMBRAVE Part A is a randomized, placebo-controlled Phase 1/2 trial evaluating the safety and efficacy of ascending doses of elsunersen in patients with SCN2A DEE. Nine patients, aged 2-12 years old, were randomized 3:1 to receive either elsunersen or sham procedure every 4 weeks for 24 weeks, followed by an open-label extension (“OLE”); all 9 patients continued to the OLE. Patients received a starting dose of 1 mg with optional dose escalation based on observed seizure reduction and individual tolerability.
Key results from EMBRAVE Part A
Efficacy
•Elsunersen treatment led to a 77% placebo-adjusted seizure reduction from baseline (p=0.015, 95 CI [33,92]).
•57% of patients had at least a 28-day period of seizure freedom.
•Efficacy was sustained in the OLE for up to one year.
•100% of elsunersen patients improved across sleep, motor function, muscle tone, attention or neuropsychomotor development compared to no improvements in placebo group.
Safety
•Elsunersen was well-tolerated, with no drug-related serious adverse events, no discontinuations and no neuroinflammation signals at doses up to 8 mg.
•Most treatment-emergent adverse events (“TEAEs”) were mild to moderate. TEAEs were consistent with the EMBRAVE Part 1 study.
Relutrigine
The U.S. Food and Drug Administration (the “FDA”) has accepted for priority review the Company’s New Drug Application for relutrigine for the treatment of SCN2A and SCN8A DEEs. The FDA has set a target action date under the Prescription Drug User Fee Act of September 27, 2026.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PRAXIS PRECISION MEDICINES, INC.
Date: April 6, 2026By: /s/ Marcio Souza
 Marcio Souza
 Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Praxis Precision Medicines (PRAX) report from the elsunersen EMBRAVE Part A trial?

Praxis reported positive topline Phase 1/2 data for elsunersen in pediatric SCN2A DEE. Elsunersen produced a 77% placebo-adjusted seizure reduction and 57% of patients had at least a 28-day seizure-free period, with benefits sustained in an open-label extension for up to one year.

How strong were the seizure reduction results for elsunersen in PRAX’s EMBRAVE study?

Elsunersen achieved a 77% placebo-adjusted seizure reduction from baseline with p=0.015 and a 95% confidence interval of 33–92. Additionally, 57% of patients experienced at least a 28-day period of seizure freedom, indicating meaningful control in this severe pediatric epilepsy population.

What safety profile did elsunersen show in Praxis Precision Medicines’ EMBRAVE Part A trial?

Elsunersen was well-tolerated in EMBRAVE Part A, with no drug-related serious adverse events, no discontinuations and no neuroinflammation signals at doses up to 8 mg. Most treatment-emergent adverse events were mild to moderate and consistent with the earlier EMBRAVE Part 1 study.

Did Praxis Precision Medicines observe functional improvements with elsunersen beyond seizure reduction?

Yes. All elsunersen-treated patients showed improvements in areas such as sleep, motor function, muscle tone, attention or neuropsychomotor development, while no patients in the placebo group improved. These changes suggest potential broader neurodevelopmental benefits alongside seizure control in SCN2A DEE.

What regulatory update did PRAX announce for relutrigine in SCN2A and SCN8A DEEs?

Praxis announced that the FDA accepted its New Drug Application for relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies for priority review. The FDA set a Prescription Drug User Fee Act target action date of September 27, 2026 for its decision.

How many patients were included in the EMBRAVE Part A elsunersen trial and what was the design?

The EMBRAVE Part A trial enrolled nine pediatric patients aged 2–12 years with SCN2A DEE, randomized 3:1 to elsunersen or sham. They received treatment every four weeks for 24 weeks, with optional dose escalation from 1 mg, followed by continuation in an open-label extension.

Filing Exhibits & Attachments

3 documents

Other Documents